Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Agios (AGIO) Reports Narrower-than-Expected Loss in Q1

Cambridge, MA-based Agios Pharmaceuticals, Inc. AGIO is focused on the development of treatments for cancer and rare genetic metabolic disorders.

Currently, the company has several interesting candidates in its pipeline out of which the most advanced are AG-221 (IDH2 mutant inhibitor – phase III study on the candidate versus standard of care chemotherapy in relapsed/refractory acute myeloid leukemia/AML patients presently in progress) and AG-120 (IDH1 mutant inhibitor – phase III study in frontline AML patients to be initiated in the second half of 2016).

Apart from these, Agios’ pipeline includes AG-881 (pan-IDH mutant inhibitor), which is currently in phase I dose escalation and expansion studies for hematological malignancies and solid tumors. Meanwhile, the company plans to present first data from the phase II DRIVE pyruvate kinase deficiency (PK) study on AG-348 for transfusion-independent patients with PK deficiency next month.

Revenues at Agios mainly consist of collaboration revenues under its agreement with Celgene Corporation. Agios is in collaboration with Celgene for AG-221, AG-120 and AG-881.

With no approved products in its portfolio, investor focus should remain on the company’s pipeline updates since a number of pipeline-related activities are lined up for 2016.

Agios’ performance so far has been disappointing with the company missing expectations in three of the last four reported quarters. Overall, the company has delivered an average negative miss of 74.70%.

Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: Agios posted narrower-than-expected loss in the first quarter of 2016. Our consensus called for a loss of 69 cents per share, and the company reported a loss of 61 cents per share.

Revenues: Revenues in the reported quarter came in above expectations. Agios posted revenues of $31.3 million, compared to our consensus estimate of $22.3 million.

Key Stats: Agios continues to progress with its pipeline. In Mar 2016, Agios announced the initiation of a phase I/II study on AG-221 or AG-120 in combination with Vidaza in patients with newly diagnosed AML who are not eligible for intensive chemotherapy. The company plans to initiate several frontline as well combination studies on these candidates during the course of the year.

Check back later for our full write up on AGIO earnings report later!

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AGIOS PHARMACT (AGIO): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research